Canada’s Listed Issuer Financing Exemption, commonly referred to as LIFE, has become a significantly more important financing option for Canadian public companies.
Introduced in 2022, LIFE was designed to give eligible exchange-listed reporting issuers a more efficient way to raise capital without preparing a prospectus. In May 2025, Canadian securities regulators substantially increased the amount qualifying issuers could raise under the exemption.
Now, the Canadian Securities Administrators are proposing to make those higher limits part of the permanent national rule.
For Canadian listed companies, the change is important. LIFE is no longer simply an alternative for relatively small financings. Depending on an issuer’s market value and capital structure, it can potentially support a much more meaningful capital raise.
But higher limits do not mean LIFE is automatically the right financing structure for every issuer.
What Is the LIFE Exemption?
The Listed Issuer Financing Exemption is contained in National Instrument 45-106 – Prospectus Exemptions. It allows qualifying Canadian reporting issuers to distribute certain securities without preparing and filing a prospectus.
One important feature is that securities issued under the exemption are generally freely tradeable under Canadian securities laws, rather than being subject to the four-month hold period commonly associated with many private placements. Source: Canadian Securities Administrators, adoption of the Listed Issuer Financing Exemption.
That can make LIFE attractive to both issuers and investors. However, the exemption is not available to every company.
Among other requirements, an issuer generally must have been a reporting issuer in at least one Canadian jurisdiction for the preceding 12 months, have listed equity securities and be current with required periodic and timely disclosure filings. The exemption is also not intended for issuers whose operations have ceased or whose principal asset is cash, cash equivalents or an exchange listing.
LIFE is therefore principally a post-listing financing tool.
A private company cannot use LIFE to finance its initial listing, and a company should not assume that completing an IPO, reverse takeover or CPC Qualifying Transaction immediately gives it access to the exemption.
The Financing Limits Increased Significantly
When LIFE was introduced, an eligible issuer could generally raise the greater of $5 million or 10% of its market capitalization, subject to a maximum of $10 million during a 12-month period.
In May 2025, the Canadian Securities Administrators introduced coordinated blanket relief that substantially increased those limits.
Under the current relief, an eligible issuer may generally raise the greater of:
- $25 million; or
- 20% of the aggregate market value of its listed securities,
subject to an overall maximum of $50 million during a 12-month period and other conditions, including an overall 50% dilution limit. Source: Canadian Securities Administrators, May 14, 2025.
The practical result is significant. A financing exemption that was originally capped at $10 million can now potentially accommodate financings several times larger.
The CSA Is Proposing to Make the Higher Limits Permanent
On July 23, 2026, the Canadian Securities Administrators published proposed amendments to National Instrument 45-106 and corresponding changes to its companion policy.
The proposal would primarily codify the higher financing limits introduced through the 2025 blanket orders and would also address other conditions of the exemption.
The CSA reported that the higher limits had materially increased use of LIFE. In the first year after the 2025 blanket order, issuers raised approximately $3.7 billion under the exemption, representing a pace of capital raising about eight times higher than under the original limits.
The comment period on the proposed amendments closes October 21, 2026. Source: Canadian Securities Administrators, July 23, 2026 consultation.
Bigger Limits Do Not Mean Every Issuer Should Use LIFE
The increased financing limits naturally make LIFE more relevant to a wider range of public companies.
But the first question for management should not simply be, “How much can we raise under LIFE?”
The more important question is whether LIFE fits the company’s broader financing and capital-markets strategy.
An issuer still has to consider its trading market, share price, market capitalization, existing shareholder base, expected capital requirements, dilution, use of proceeds and ability to attract investors.
The theoretical maximum permitted under the exemption may be very different from the amount a company can realistically finance on acceptable terms.
Dilution and Capital Structure Still Matter
The expanded limits do not eliminate dilution considerations.
Under the current blanket-order relief and the proposed amendments, LIFE financings remain subject to an overall 50% dilution limit calculated under the applicable rules.
For smaller-cap issuers, dilution can become a central strategic consideration. A company may be able to raise additional capital under the exemption but still need to evaluate how the proposed financing could affect existing shareholders, control, future financings and the market’s perception of the issuer.
A financing that provides needed capital but leaves the company with a difficult capital structure can create problems later.
The financing structure matters as much as the exemption used to complete it.
LIFE Is One Financing Route, Not a Financing Strategy
LIFE should be considered alongside the issuer’s other available capital-raising alternatives.
Depending on the company and transaction, those alternatives may include conventional private placements, prospectus financings, strategic investments, rights offerings, debt or convertible securities and other available prospectus exemptions.
Each structure can have different implications for timing, investor eligibility, resale restrictions, financing cost, dilution, disclosure and the role of registered dealers.
Management should therefore consider LIFE within the company’s broader capital plan rather than treating the exemption as an isolated regulatory solution.
Why LIFE Matters Before a Company Goes Public
Although a private company cannot generally use LIFE to finance its initial Canadian listing, the exemption can still be relevant when planning to go public in Canada.
Companies frequently focus on the capital required to complete an IPO, reverse takeover or CPC Qualifying Transaction.
They often spend less time considering the capital that may be required six, twelve or eighteen months after the listing is completed.
A credible going-public plan should address more than the financing completed at closing. It should also consider expected post-listing working capital, future financing requirements, the resulting capital structure, expected investor base and the company’s ability to access additional capital once it has established the required reporting-issuer history.
For some companies, LIFE may eventually become an important part of that post-listing financing strategy.
The Exemption Does Not Create Investor Demand
There is another distinction companies should keep in mind.
A regulatory exemption provides a framework through which an eligible issuer can distribute securities. It does not create a market for those securities.
A successful financing still depends on the company’s business, stage of development, valuation, market conditions, management credibility, shareholder support, investor relationships, liquidity, use of proceeds and transaction terms.
The increase in LIFE limits gives eligible issuers greater financing flexibility. It does not replace the need for a credible capital-markets strategy.
What Listed Issuers Should Be Considering
For public companies evaluating future capital requirements, the expanded LIFE exemption creates another reason to assess financing strategy before capital becomes urgent.
The discussion should go beyond whether the company technically qualifies. Management should consider how a LIFE financing would fit with the company’s existing capital structure, investor base, anticipated funding requirements and longer-term capital-markets objectives.
The same principle applies to private companies preparing to go public. The financing completed at the time of listing is only one part of the capital plan. Management should understand how the proposed public-company structure could affect its ability to raise additional capital after listing.
Bottom Line
The expansion of Canada’s Listed Issuer Financing Exemption is a meaningful development for Canadian public companies.
The ability of qualifying issuers to potentially raise up to $50 million under the expanded framework makes LIFE considerably more significant than the exemption originally introduced in 2022.
But greater financing capacity does not eliminate questions around dilution, transaction structure, investor demand, disclosure, timing or execution.
The right question is not simply whether an issuer qualifies for LIFE. It is whether LIFE fits the company’s overall financing and capital-markets strategy.
Go Public in Canada works with private and public companies on Canadian listing, financing and capital-markets strategy. If your company is evaluating a Canadian listing or its post-listing financing options, contact us to discuss the appropriate strategy and transaction structure.